FountainBlue

February 2012: What's New with FountainBlue: Advisory Boards

We are serving on the advisory boards of for select members of our community, supporting their marketing, business development and recruitment efforts. Currently, we are providing advisory and business development support Speck Design and their product innovation services http://www.speckdesign.com, and advisory and investment strategy support for Bell Biosystems and their research on heritable magnetic signature in therapeutic cells, with huge implications for diagnostics, cancer, regenerative medicine and cell therapies. http://www.bellbiosystems.com. For more information about any of these organizations and the services they provide, and more information about the organizations where we serve, visit http://www.fountainblue.biz/consulting/advisory.html.

January 16, What's New with FountainBlue: Members as Referral Partners

At the request of our members, we will be sending out our job reqs to our members, inviting everyone to strategically forward them on to their networks of contacts. Thank you in advance to everyone who elects to forward our reqs. Please tell your contacts to mention that you connected him/her to us, so that we can track the origin of our candidate leads. We are happy to pay a referral fee to members who recruit candidates who get hired and stay for a ninety-day period. You may also elect to donate your referral fee to a FountainBlue-approved nonprofit or a nonprofit of your choice. For more information about our job leads, visit http://www.fountainblue.biz/openreqs.html.

January 9, What's New with FountainBlue: Giving Back

Since our launch in January 2006, FountainBlue has been committed to giving back to the community through active participation and financial support. As we shift into recruiting and consulting, we are pleased to contribute financially to nonprofit causes providing executive education, educational benefit, and women-in-leadership. Currently we are supporting the following types of organizations:

Executive Development Organizations:

   Career Actions

Educational Organizations:

   A Schmahl Science Workshop, as a member of the advisory committee.

Women-In-Leadership organizations:

   Global Fund for Women

   Global Women Leadership Network

   Women's Initiative

Please e-mail us with the following information at info@whenshespeaks.com or complete the form above if you would like to considered an approved, adopted FountainBlue cause.

   Your name

   Recommended Nonprofit

   Your involvement with Nonprofit

   Why you would recommend this Nonprofit

   Why FountainBlue's membership of clean energy, high tech, and life science entrepreneurs would find this nonprofit beneficial to the community overall

We are happy to profile a nonprofit each month, and recommend any of these nonprofits as worthy causes.

If you’re interested in catching up over the phone or in person, please visit http://meetwith.me/lindaholroyd and suggest a good time to connect. Please also let us know if we can support you with your recruiting, consulting and coaching needs as you grow your business.

January 2 Update: A New Year, A New Newsletter Format!

We are looking forward to an exciting new year, and an exciting new time for the valley and the global community! It is our hope that our weekly newsletter will provide you with relevant, useful information about business and market trends and their implications for your business. We invite your inquiries, suggestions, feedback and interest as we continue with our consulting, coaching and recruiting efforts! If you’re interested in catching up over the phone or in person, please visit http://meetwith.me/lindaholroyd and suggest a good time to connect. Please also let us know if we can support you with your recruiting, consulting and coaching needs as you grow your business.

For the month of February 2012, we are profiling: The Big Think: The Future of Healthcare - Top 10 Trends That Are Changing Medicine, John Nosta http://www.johnnosta.com/2011/12/the-big-think-the-future-of-healthcare-top-10-trends-that-are-changing-medicine/

Healthcare is changing. Changing radically and driven by powerful forces of cost, technology and consumer empowerment. Here's what you can look for:

1. The electronic medical record. All your health records will soon be stored electronically. The don't live in a file at the doctor's office, radiologist or hospital anymore. This "instantly accessible" tool will be a significant advance for care anywhere YOU may be. Further, the emergence of the EMR will help drive superior care and less medical errors as computers can flag potential problems.
2. The clinical cloud. It's no longer only your music that will be downloadable. But soon, your health record will be digital and follow you. You CAT scan and ECG are a click away for any necessary viewing.
3. Retail Medicine. Yep, it's already there. But the medi-clinics on the corner will be replaced by chain-style medical offices that will appear in your local mall or big box store. Even retail pharmacies will expand their service to include some medical care.
4. Smart phone monitoring. Your smart phone will monitor your ECG, blood sugar, sleep patterns (to name a few) and alert you and your doctor when there's a problem. It will track and record these trends and offer valuable diagnostic information.
5. Expert engagement at a distance. Distance is no longer an issue. With video engagement and the medical cloud at hand, difficult (and even simple) cases can be evaluated by experts around the world. Even surgical procedures by physicians thousands of miles away--with the help of robotic.
6. Implantable devices. Pain, depression, and common conditions that are generally treated with pills will be successfully managed with implantable devices that use both drugs and electric current to stimulate and normalize conditions with less toxicity and superior long-term management.
7. On-line office visits. At-home diagnostic tools and data transfer to a physician's office will reduce the need for an actual office visit. Video conferencing and these diagnostic tools will provide an accurate assessment, care and risk-management.
8. The patient-doctor. The empowered patient will learn to make informed decisions based upon new at-home tools and techniques. We will measure our own blood chemistries and take and transmit our ECG's. Our actions, guided by experts will allow us to be engaged and informed.
9. Value driven intervention. Cost will emerge as a key factor in care. And value will be an important element. Patients will be rewarded for seeking cost-effective care and value seekers "shop around" procedures like CAT scans on the basis of technology and cost. Long gone will be the day of having a complex test without knowing or caring about the price.
10. The vanishing private practice. The economics of medicine are squeezing the solo practitioner.   Seeing "your" doctor at Walmart may be more likely than that small practice in your home town.

Glooko is an example of a smartphone innovation.

Glooko is an innovative Silicon Valley startup with a unique solution for people with diabetes. Their products enable users with an iPhone® and iPod touch® to easily collect and view the information they need to keep track of their glucose levels – anytime, anywhere.

With the Glooko MeterSync Cable, readings are transferred from a glucose meter into the Glooko Logbook app. From there, users can add notes, review history, and share their logbook to help them get insight into the effect their activities have on their numbers. The Glooko MeterSync Cable is compatible with many of the most popular meters on the market. 

For more information, please check out Glooko.com. The Glooko MeterSync Cable is available on Amazon.com for $39.95 and the Glooko Logbook app is available for free download from the Apple iTunes Store.

MEDgle is an example of expert engagement at a distance as well as online-office visits and the changing patient-doctor relationship with elements of value-driven intervention.

MEDgle provides the engine to transform clinical data into patient-specific, concrete, human-meaningful, information, options, and tasks. For each patient, MEDgle leverages their real-time Health Data Streams (including chronological health history) and transforms them into individualized next-step care action items and health indicators. At the macro level, we use the aggregate patient Health Data Streams and produce interactive clinical and financial predictive models so that the best care, with less time and cost, can be delivered.

Technology-wise, MEDgle is a big data health stream analytics cloud made up of over 130 million points of data, learning algorithms, and real-time big algorithms. MEDgle's specifically translates any available clinical data (age, gender, symptoms, durations, vitals, previous conditions, family history, claims) into on-demand clinical expertise such as acuity level, short and long term differential diagnosis, admission risk, investigative questions, labs, treatments, and more. Just as Intel provides chips to power computing devices, MEDgle provides cloud based APIs to EHRs, medical devices, health sensors, health social networks, and more. In addition, MEDgle is delivered as ready-to-use web/mobile applications such as Clinical GPS and BigPatient. In short, MEDgle is simplifying human health management. http://www.medgle.com

Rexanto is an example of the retail medicine and value-driven intervention trend.

Rexanto builds & operates Web2.0 managed-B2B-markets of goods & services for the Rx industry that enables transparent-pricing of goods, stimulates innovative technology-enabled services and transforms the incumbent supply chain for the pharmaceutical industry. Current Rexanto services are procurement, distribution, Rx-Packaging and Rx-Labeling of meds. Rexanto’s partnerships with UPS Healthcare, a supply chain services division with global footprint, partnerships with a network of 90 pharmacies that represents $750M in buying power, and relationships with suppliers, including seven generic med suppliers position Rexanto for rapid adoption, expansion and growth. Over the next quarter, Rexanto will be focusing on building relationships with assisted living facilities, and welcome your thoughts and connections in this area. For more information, visit http://www.rexanto.com.

For the month of January 2012, we are profiling ‘Science Trends in 2012: Developments to Expect’, by IB Times Science Desk, Dec 22, 2011

The biotech market did well in 2011, a trend expected to continue into 2012, analysts say, though the pharmaceutical sector is expected to struggle as many drug patents expire. The S&P 500 Biotechnology Sub-Industry Index gained 15.7 percent in 2011 and even during the last three volatile months of 2011, gained 4.9 percent, according to data compiled from The Street.

"Continued merger and acquisition activity and favorable legislation will be key growth drivers, while an aging population and environmental concerns could spur demand in the industry," wrote analysts with Karvy Global Services, a Wall Street research firm. While the biotech market could gain in 2012, the outlook for the pharmaceutical industry is gloomier as drug patents continue to expire in the upcoming year. In 2011, the patent expired for Lipitor, the cholesterol drug Pfizer with 2010 sales of $13 billion.

http://www.ibtimes.com/articles/271686/20111222/science-trends-2012-developments-expect.htm

Our January 9 profiled company is Heartflow, which has come out of stealth with the announcement of a 75M round of capital with U.S. Venture Partners as a new investor.

HeartFlow is a venture backed cardiovascular diagnostics company located in Redwood City. Its FFRCT technology is based on 15 years of scientific research at Stanford University and is the gold standard for determining whether patients with coronary artery disease require treatment, either with balloons, stents, or coronary artery bypass grafts (CABG)1,2. HeartFlow’s FFRCT analysis uses the power of high-performance computing and image data from computed tomography (CT) scans to provide physicians with data about blood flow within the coronary arteries, which enables the computation of FFR in a non-invasive manner. A HeartFlow DISCOVER-FLOW study was recently published in the Journal of the American College of Cardiology and EuroPCR 2011. Data and results from this study show a 25% improvement in per-vessel diagnostic accuracy as compared to a standard CT scan3. http://www.Heartflow.com

If you are interested in nominating a company for an upcoming newsletter on this month's trend, please visit or e-mail your profile to info@svlifescience.com with the following information:

Name and Company:

100-word description of why it is innovative:

Link for more information

URL with picture of innovation

Give Us Feedback

Please let us know how we can better provide value to you as a member.

We welcome your program ideas and suggestions.

We welcome your ideas on how we can enhance our green commitment.

We welcome your active participation in other ways.